Literature DB >> 11773506

The inhibitory effect of soy protein isolate on atherosclerosis in mice does not require the presence of LDL receptors or alteration of plasma lipoproteins.

Michael R Adams1, Deborah L Golden, Mary S Anthony, Thomas C Register, J Koudy Williams.   

Abstract

The mechanisms by which dietary soy favorably influences lipoprotein metabolism and inhibits atherosclerosis are uncertain. Studies of blood mononuclear cells and cultured hepatocytes have indicated that certain soy peptides (i.e., 7S globulins) stimulate expression of LDL receptors. This pathway represents a hypothetical mechanism by which soy's hypocholesterolemic and antiatherosclerotic effects may be mediated. However, direct evidence supporting this hypothesis is lacking. To address this, we compared effects of dietary soy protein isolate in two genetically engineered mouse models of atherosclerosis. One mouse [LDL receptor -/- + apolipoprotein (apo) B transgenic] is devoid of LDL receptors and overproduces apolipoprotein B, whereas the other (apoE -/-) has a normal complement of LDL receptors but does not produce apolipoprotein E. Male (n = 10-12/group) and ovariectomized female (n = 10-12/group) mice were studied. There were three treatment groups, which differed principally by the source of the protein component of the diet: 1) casein/lactalbumin (no isoflavones), 2) alcohol-washed soy protein isolate (total isoflavones = 0.04 mg/g), and 3) intact soy protein isolate (total isoflavones = 1.72 mg/g). Atherosclerosis was assessed by quantifying the aortic content of esterified cholesterol. Atherosclerosis was inhibited (relative to the casein/lactalbumin group) by both alcohol-washed (45 and 31%) (P < 0.05) and intact (65 and 41%) (P < 0.05) soy protein isolate in LDL receptor -/- and apoE -/- mice, respectively. There was no sex difference. In a two-way analysis, there were significant effects of type of soy isolate and type of mouse. The antiatherosclerosis effect was enhanced in LDL receptor -/- mice (P < 0.001) and diminished in mice fed alcohol-washed soy protein isolate (P < 0.001). Furthermore, inhibitory effects of soy on atherosclerosis were unrelated to plasma LDL, VLDL or HDL cholesterol concentrations. The results represent direct evidence for the existence of LDL receptor- and plasma lipoprotein-independent pathways by which dietary soy protein isolate inhibits atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773506     DOI: 10.1093/jn/132.1.43

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  10 in total

1.  Soy protein diet and exercise training increase relative bone volume and enhance bone microarchitecture in a mouse model of uremia.

Authors:  Emily J Tomayko; Hae R Chung; Kenneth R Wilund
Journal:  J Bone Miner Metab       Date:  2011-06-03       Impact factor: 2.626

2.  Soy protein containing isoflavones favorably influences macrophage lipoprotein metabolism but not the development of atherosclerosis in CETP transgenic mice.

Authors:  Leiko Asakura; Patrícia M Cazita; Lila M Harada; Valéria S Nunes; Jairo A Berti; Alessandro G Salerno; Daniel F J Ketelhuth; Magnus Gidlund; Helena C F Oliveira; Eder C R Quintão
Journal:  Lipids       Date:  2006-07       Impact factor: 1.880

Review 3.  Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk.

Authors:  Vanessa Bianconi; Massimo Raffaele Mannarino; Amirhossein Sahebkar; Teresa Cosentino; Matteo Pirro
Journal:  Curr Cardiol Rep       Date:  2018-05-25       Impact factor: 2.931

4.  Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial.

Authors:  Howard N Hodis; Wendy J Mack; Naoko Kono; Stanley P Azen; Donna Shoupe; Juliana Hwang-Levine; Diana Petitti; Lora Whitfield-Maxwell; Mingzhu Yan; Adrian A Franke; Robert H Selzer
Journal:  Stroke       Date:  2011-09-08       Impact factor: 7.914

5.  Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older apoE deficient mice.

Authors:  Michelle M Averill; Brian J Bennett; Marcello Rattazzi; Rebecca M Rodmyre; Elizabeth A Kirk; Stephen M Schwartz; Michael E Rosenfeld
Journal:  Atherosclerosis       Date:  2008-07-01       Impact factor: 5.162

6.  Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats.

Authors:  Chao Wu Xiao; Carla M Wood; Dorcas Weber; Syed A Aziz; Rekha Mehta; Philip Griffin; Kevin A Cockell
Journal:  Genes Nutr       Date:  2013-11-30       Impact factor: 5.523

7.  Can stevioside in combination with a soy-based dietary supplement be a new useful treatment of type 2 diabetes? An in vivo study in the diabetic goto-kakizaki rat.

Authors:  Per B Jeppesen; Stig E Dyrskog; Andreas Agger; Soren Gregersen; Michele Colombo; Jianzhong Xiao; Kjeld Hermansen
Journal:  Rev Diabet Stud       Date:  2007-02-10

8.  Soy protein inhibits inflammation-induced VCAM-1 and inflammatory cytokine induction by inhibiting the NF-κB and AKT signaling pathway in apolipoprotein E-deficient mice.

Authors:  Ramona L Burris; Hang-Pong Ng; Shanmugam Nagarajan
Journal:  Eur J Nutr       Date:  2013-03-07       Impact factor: 5.614

9.  Dietary Avian Proteins Are Comparable to Soybean Proteins on the Atherosclerosis Development and Fatty Liver Disease in Apoe-Deficient Mice.

Authors:  Roberto Martínez-Beamonte; Javier Sánchez-Marco; Gonzalo Lázaro; María Barco; Tania Herrero-Continente; Marta Serrano-Megías; David Botaya; Carmen Arnal; Cristina Barranquero; Joaquín C Surra; Jesús Osada; María A Navarro
Journal:  Nutrients       Date:  2021-05-27       Impact factor: 5.717

10.  A Novel Peptide from Soybean Protein Isolate Significantly Enhances Resistance of the Organism under Oxidative Stress.

Authors:  Heran Ma; Rui Liu; Ziyuan Zhao; Zhixian Zhang; Yue Cao; Yudan Ma; Yi Guo; Li Xu
Journal:  PLoS One       Date:  2016-07-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.